Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.
Website: resmed.com



Growth: Pretty weak revenue growth rate 9.1%, there is slowdown compared to average historical growth rates 13.4%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -4.6%

Profitability: LTM EBITDA margin is positive, +37.0%. On average the margin is improving unsteadily. Gross margin is high, +61.5%. In the last quarter the company beat the estimated EPS, +5.7%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.9%. Free cash flow yield 2.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 81.8% higher than minimum and 16.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.9x by EV / Sales multiple , the company can be 41.6% overvalued

Insiders: For the last 3 months insiders sold company shares on $7.9 mln (-0.022% of cap.)

Key Financials (Download financials)

Ticker: RMD
Share price, USD:  (0.0%)244.81
year average price 250.53  


year start price 233.82 2025-01-11

min close price 204.54 2025-04-08

max close price 293.73 2025-08-22

current price 244.81 2026-01-11
Common stocks: 146 182 000

Dividend Yield:  0.9%
FCF Yield LTM: 2.7%
EV / LTM EBITDA: 18.1x
EV / EBITDA annualized: 17.8x
Last revenue growth (y/y):  +9.1%
Last growth of EBITDA (y/y):  +14.4%
Historical revenue growth:  +13.4%
Historical growth of EBITDA:  +19.0%
EV / Sales: 6.7x
Margin (EBITDA LTM / Revenue): 37.0%
Fundamental value created in LTM:
Market Cap ($m): 35 787
Net Debt ($m): -537
EV (Enterprise Value): 35 250
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-30zacks.com

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-12-03zacks.com

Should You Continue to Hold RMD Stock in Your Portfolio?

2025-11-24forbes.com

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

2025-10-30seekingalpha.com

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

2025-10-30zacks.com

ResMed (RMD) Q1 Earnings and Revenues Beat Estimates

2025-10-29zacks.com

Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

2025-09-23seekingalpha.com

ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript

2025-09-12zacks.com

Here's Why ResMed (RMD) is a Strong Growth Stock

2025-09-08youtube.com

The sleep economy is 'having a moment', says medical equipment firm Resmed

2025-08-27seekingalpha.com

ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2025-08-08 2024-10-25 2024-08-09 2024-04-26 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2026 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 1 336M 1 348M 1 225M 1 223M 1 197M 1 163M 963M 1 122M 1 117M 1 034M 950M
costOfRevenue 515M 528M 507M 519M 515M 516M 363M 505M 499M 454M 409M
grossProfit 821M 820M 717M 704M 682M 647M 600M 617M 618M 580M 541M
grossProfitRatio 0.615 0.608 0.586 0.576 0.569 0.556 0.623 0.55 0.553 0.561 0.569
researchAndDevelopmentExpenses 87M 86M 80M 81M 77M 74M 76M 78M 76M 70M 63M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 259M 265M 239M 242M 230M 222M 223M 241M 228M 212M 194M
otherExpenses 28M 14M 11M -3M -2M -686 000 12M 61 000 12M 10M 8M
operatingExpenses 374M 366M 330M 323M 307M 308M 311M 331M 317M 291M 265M
costAndExpenses 889M 893M 837M 842M 822M 823M 674M 836M 816M 745M 675M
interestIncome 0 6M 0 4M 0 0 18M 0 0 0 0
interestExpense 9M 0 0 10M -11M -14M -15M -15M -15M -10M -7M
depreciationAndAmortization 48M 74M 54M 55M 55M 53M 53M 55M 46M 62M 23M
ebitda 503M 532M 443M 422M 429M 457M 289M 334M 347M 343M 299M
ebitdaratio 0.377 0.395 0.362 0.356 0.359 0.393 0.3 0.297 0.311 0.331 0.314
operatingIncome 447M 455M 387M 381M 375M 275M 289M 275M 301M 280M 276M
operatingIncomeRatio 0.334 0.337 0.316 0.312 0.313 0.237 0.3 0.245 0.269 0.271 0.29
totalOtherIncomeExpensesNet 256 000 4M -4M -23M 837 000 -66M -17M 6M -11M -7M -14M
incomeBeforeTax 447M 458M 383M 358M 375M 259M 272M 277M 289M 274M 262M
incomeBeforeTaxRatio 0.335 0.34 0.313 0.292 0.314 0.223 0.283 0.247 0.259 0.265 0.275
incomeTaxExpense 98M 78M 72M 65M 75M 51M 53M 47M 57M 49M 51M
netIncome 349M 380M 311M 292M 300M 209M 219M 230M 233M 225M 210M
netIncomeRatio 0.261 0.282 0.254 0.239 0.251 0.18 0.228 0.205 0.208 0.218 0.221
eps 2.38 2.59 2.12 1.99 2.04 1.42 1.49 1.56 1.58 1.53 1.44
epsdiluted 2.37 2.58 2.11 1.98 2.04 1.42 1.49 1.56 1.58 1.53 1.43
weightedAverageShsOut 146M 146M 147M 147M 147M 147M 147M 147M 147M 147M 146M
weightedAverageShsOutDil 147M 147M 148M 148M 147M 148M 147M 148M 147M 147M 147M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2025-08-08 2024-10-25 2024-08-09 2024-04-26 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2026 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M
shortTermInvestments 0 0 0 12M 22M 8M 12M 0 0 0 0
cashAndShortTermInvestments 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M
netReceivables 958M 991M 811M 837M 817M 730M 692M 705M 686M 672M 620M
inventory 946M 928M 918M 822M 829M 933M 958M 998M 1 011M 989M 865M
otherCurrentAssets 338M 378M 486M 460M 467M 180M 445M 437M 412M 147M 341M
totalCurrentAssets 3 626M 3 506M 2 641M 2 358M 2 351M 2 378M 2 305M 2 368M 2 338M 2 325M 2 034M
propertyPlantEquipmentNet 726M 718M 717M 699M 687M 705M 657M 666M 656M 651M 613M
goodwill 3 044M 3 047M 2 886M 2 842M 2 836M 2 862M 2 812M 2 770M 2 784M 2 767M 1 939M
intangibleAssets 447M 465M 479M 486M 501M 528M 563M 552M 570M 587M 338M
goodwillAndIntangibleAssets 3 491M 3 512M 3 365M 3 328M 3 337M 3 390M 3 375M 3 323M 3 353M 3 354M 2 277M
longTermInvestments 165M 85M 0 170M 175M 160M -265M -395M 0 -346M 0
taxAssets 276M 253M 221M 204M 162M 156M 403M 395M 96M 346M 81M
otherNonCurrentAssets 25M 101M 279M 114M 102M 116M 265M 395M 271M 346M 173M
totalNonCurrentAssets 4 683M 4 669M 4 581M 4 515M 4 463M 4 527M 4 436M 4 384M 4 376M 4 351M 3 144M
otherAssets 0 0 0 0 0 0 0 0 0 0 0
totalAssets 8 308M 8 174M 7 222M 6 872M 6 815M 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
accountPayables 267M 278M 249M 238M 177M 202M 177M 151M 162M 196M 181M
shortTermDebt 290M 40M 38M 60M 34M 34M 32M 32M 33M 32M 31M
taxPayables 135M 132M 94M 108M 55M 47M 67M 72M 78M 58M 48M
deferredRevenue 168M 166M 157M 153M 151M 149M 147M 138M 141M 134M 108M
otherCurrentLiabilities 396M 402M 366M 352M 411M 379M 415M 438M 426M 370M 372M
totalCurrentLiabilities 1 256M 1 019M 904M 911M 773M 764M 771M 759M 762M 733M 693M
longTermDebt 556M 811M 812M 839M 997M 1 357M 1 464M 1 548M 1 691M 1 907M 900M
deferredRevenueNonCurrent 159M 157M 144M 137M 132M 127M 121M 119M 109M 103M 98M
deferredTaxLiabilitiesNonCurrent 78M 78M 84M 79M 87M 89M 88M 91M 113M 108M 12M
otherNonCurrentLiabilities 138M 142M 83M 42M 196M 85M 46M 105M 107M 88M 731M
totalNonCurrentLiabilities 932M 1 187M 1 123M 1 098M 1 412M 1 659M 1 720M 1 863M 2 020M 2 205M 1 052M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 178M 184M 173M 167M 136M 165M 134M 139M 138M 139M 135M
totalLiabilities 2 187M 2 207M 2 027M 2 008M 2 185M 2 423M 2 490M 2 622M 2 781M 2 938M 1 745M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 762 000 761 000 758 000 588 000 588 000 588 000 588 000 588 000 588 000 588 000 586 000
retainedEarnings 6 342M 6 081M 5 225M 4 992M 4 770M 4 540M 4 402M 4 253M 4 088M 3 920M 3 760M
accumulatedOtherComprehensiveIncomeLoss -61M -75M -132M -252M -265M -208M -320M -273M -262M -270M -406M
othertotalStockholdersEquity -161M -40M 101M 123M 125M 150M 168M 149M 106M 88M 79M
totalStockholdersEquity 6 121M 5 968M 5 195M 4 864M 4 630M 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M
totalEquity 6 121M 5 968M 5 195M 4 864M 4 630M 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M
totalLiabilitiesAndStockholdersEquity 8 308M 8 174M 7 222M 6 872M 6 815M 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 8 308M 8 174M 7 222M 6 872M 6 815M 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M
totalInvestments 165M 85M -279M 170M 175M 160M -265M -395M 0 -346M 0
totalDebt 846M 852M 850M 874M 1 167M 1 391M 1 496M 1 580M 1 724M 1 939M 931M
netDebt -537M -358M 424M 636M 930M 1 181M 1 287M 1 352M 1 496M 1 686M 723M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2025-08-08 2024-10-25 2024-08-09 2024-04-26 2024-01-25 2023-10-27 2023-08-11 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57
calendarYear 2026 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome 349M 380M 311M 292M 300M 209M 219M 230M 233M 225M 210M
depreciationAndAmortization 58M 74M 54M 55M 55M 53M 53M 55M 53M 46M 44M
deferredIncomeTax 0 0 0 -10M 0 44M -33M 7M 0 0 0
stockBasedCompensation 21M 25M 20M 21M 20M 20M 19M 20M 18M 16M 17M
changeInWorkingCapital 25M 10M -59M 57M 41M -44M -10M -63M -14M -153M -232M
accountsReceivables 30M -5M 36M -58M -56M -27M 7M -18M -13M -20M -56M
inventory -15M -32M -70M 9M 86M 50M 27M 6M -22M -86M -147M
accountsPayables 0 0 -25M 44M 0 -44M 0 330 000 0 0 8M
otherWorkingCapital 10M 47M -123 000 106M 11M -23M -33M -52M 20M -47M -37M
otherNonCashItems 5M 50M -283 000 194M 86M -9M 38M -11M -6M -6M 5M
netCashProvidedByOperatingActivities 457M 539M 326M 440M 402M 273M 286M 237M 283M 129M 45M
investmentsInPropertyPlantAndEquipment -43M -34M -18M -26M -23M -25M -41M -39M -31M -32M -32M
acquisitionsNet -522 000 -139M 0 -20M -3M -8M -103M -2M -13M -992M -19M
purchasesOfInvestments -2M -2M -1M -3M -2M -9M -5M -6M -13M -13M -7M
salesMaturitiesOfInvestments 0 250 000 23M 750 000 0 5M 250 000 4M 16M 10M 0
otherInvestingActivites -7M 40M -2M 2M -5M -5M -2M -4M 13M 0 0
netCashUsedForInvestingActivites -53M -134M 2M -47M -33M -41M -149M -47M -28M -1 026M -59M
debtRepayment 0 -5M -30M -300M -220M -130M -185M -145M -215M -15M -30M
commonStockIssued 8M 30M 8M 28M 5M 20M 983 000 23M 983 000 22M 3M
commonStockRepurchased -150M -100M -50M -50M -50M -50M 105M 0 0 0 0
dividendsPaid -88M -78M -78M -71M -70M -71M -71M -65M -65M -65M -64M
otherFinancingActivites -719 000 -11M -1M -421 000 -314 000 -8M -2M -2M -900 000 990M 50M
netCashUsedProvidedByFinancingActivities -230M -164M -151M -393M -336M -239M -151M -189M -280M 933M -42M
effectOfForexChangesOnCash -71 000 36M 11M 129 000 -5M 8M -5M -2M -208 000 11M -11M
netChangeInCash 174M 277M 188M 451 000 28M 1M -19M -3000 -25M 46M -67M
cashAtEndOfPeriod 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M
cashAtBeginningOfPeriod 1 209M 933M 238M 238M 210M 209M 228M 228M 253M 207M 274M
operatingCashFlow 457M 539M 326M 440M 402M 273M 286M 237M 283M 129M 45M
capitalExpenditure -43M -31M -20M -26M -23M -25M -41M -39M -31M -32M -32M
freeCashFlow 414M 508M 306M 414M 379M 248M 245M 199M 251M 97M 12M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2026 q1)
2025 q2
2025-07-31 ET (fiscal 2025 q4)
2025 q1
2025-04-23 ET (fiscal 2025 q3)
2024 q4
2025-01-30 ET (fiscal 2025 q2)
2024 q3
2024-10-24 ET (fiscal 2025 q1)
2024 q2
2024-08-01 ET (fiscal 2024 q4)
2024 q1
2024-04-25 ET (fiscal 2024 q3)
2023 q4
2024-01-24 ET (fiscal 2024 q2)
2023 q3
2023-10-26 ET (fiscal 2024 q1)
2023 q2
2023-08-03 ET (fiscal 2023 q4)
2023 q1
2023-04-27 ET (fiscal 2023 q3)
2022 q4
2023-01-26 ET (fiscal 2023 q2)
2022 q3
2022-10-27 ET (fiscal 2023 q1)
2022 q2
2022-08-11 ET (fiscal 2022 q4)
2022 q1
2022-04-28 ET (fiscal 2022 q3)
2021 q4
2022-01-27 ET (fiscal 2022 q2)
2021 q3
2021-10-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-10-30 20:06 ET
ResMed reported for 2025 q3
SEC form 8
2025-10-30 20:06 ET
ResMed published news for 2025 q3
SEC form 8
2025-07-31 20:05 ET
ResMed reported for 2025 q2
SEC form 8
2025-07-31 20:05 ET
ResMed published news for 2025 q2
SEC form 10
2025-04-24 00:00 ET
ResMed published news for 2025 q1
SEC form 10
2025-04-23 22:20 ET
ResMed published news for 2025 q1
SEC form 8
2025-04-23 20:05 ET
ResMed reported for 2025 q1
SEC form 8
2025-04-23 20:05 ET
ResMed published news for 2025 q1
SEC form 10
2025-01-31 00:08 ET
ResMed published news for 2024 q4
SEC form 10
2025-01-31 00:00 ET
ResMed reported for 2024 q4
SEC form 8
2025-01-30 16:05 ET
ResMed published news for 2024 q4
SEC form 8
2025-01-30 16:05 ET
ResMed published news for 2024 q4
SEC form 10
2024-10-25 00:00 ET
ResMed reported for 2024 q3
SEC form 10
2024-10-24 19:37 ET
ResMed published news for 2024 q3
SEC form 8
2024-10-24 00:00 ET
ResMed published news for 2024 q3
SEC form 8
2024-10-24 00:00 ET
ResMed published news for 2024 q3
SEC form 10
2024-08-09 00:00 ET
ResMed published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
ResMed published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
ResMed reported for 2024 q2
SEC form 10
2024-04-26 00:00 ET
ResMed published news for 2024 q1
SEC form 10
2024-04-25 19:18 ET
ResMed published news for 2024 q1
SEC form 8
2024-04-25 16:07 ET
ResMed published news for 2024 q1
SEC form 8
2024-04-25 16:07 ET
ResMed reported for 2024 q1
SEC form 10
2024-01-25 00:00 ET
ResMed published news for 2023 q4
SEC form 10
2024-01-24 19:50 ET
ResMed published news for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed reported for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed published news for 2023 q4
SEC form 10
2023-10-27 00:00 ET
ResMed published news for 2023 q3
SEC form 10
2023-10-26 19:38 ET
ResMed published news for 2023 q3
SEC form 8
2023-10-26 16:05 ET
ResMed reported for 2023 q3
SEC form 10
2023-08-11 00:00 ET
ResMed published news for 2023 q2
SEC form 6
2023-08-03 16:06 ET
ResMed reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
ResMed published news for 2023 q2
SEC form 10
2023-04-28 00:00 ET
ResMed published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
ResMed published news for 2023 q1
SEC form 6
2023-03-30 16:36 ET
ResMed published news for 2022 q4
SEC form 10
2023-01-27 00:00 ET
ResMed reported for 2022 q4
SEC form 10
2023-01-26 18:09 ET
ResMed reported for 2022 q4
SEC form 6
2023-01-26 16:05 ET
ResMed published news for 2022 q4
SEC form 8
2023-01-26 00:00 ET
ResMed reported for 2022 q4
SEC form 6
2022-11-17 16:08 ET
ResMed published news for 2022 q3
SEC form 10
2022-10-28 00:00 ET
ResMed reported for 2022 q3
SEC form 10
2022-10-27 18:26 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-27 16:05 ET
ResMed published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-05 14:02 ET
ResMed published news for 2022 q3
SEC form 10
2022-08-12 00:00 ET
ResMed reported for 2022 q2
SEC form 10
2022-08-11 21:09 ET
ResMed reported for 2022 q2
SEC form 6
2022-08-11 20:57 ET
ResMed published news for 2022 q2
SEC form 6
2022-08-11 16:07 ET
ResMed published news for 2022 q2
SEC form 8
2022-08-11 00:00 ET
ResMed reported for 2022 q2
SEC form 6
2022-07-01 13:03 ET
ResMed published news for 2022 q2
SEC form 6
2022-06-30 17:28 ET
ResMed published news for 2022 q1
SEC form 6
2022-06-14 09:07 ET
ResMed published news for 2022 q1
SEC form 6
2022-05-11 16:28 ET
ResMed published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-04-28 18:47 ET
ResMed reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
ResMed published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-01-28 00:00 ET
ResMed published news for 2021 q4
SEC form 10
2022-01-27 18:21 ET
ResMed published news for 2021 q4
SEC form 6
2022-01-27 16:06 ET
ResMed published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
ResMed published news for 2021 q4
SEC form 6
2021-11-19 14:31 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-28 18:28 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-28 16:07 ET
ResMed published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-07 14:03 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-06 12:08 ET
ResMed published news for 2021 q3
SEC form 6
2021-09-13 16:01 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-27 16:06 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-19 10:23 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-17 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-16 21:43 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-05 16:08 ET
ResMed published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
ResMed published news for 2021 q1
SEC form 10
2021-04-29 19:50 ET
ResMed published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
ResMed published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
ResMed published news for 2021 q1
SEC form 6
2021-03-29 17:54 ET
ResMed published news for 2020 q4
SEC form 10
2021-01-28 17:55 ET
ResMed published news for 2020 q4
SEC form 6
2021-01-28 16:05 ET
ResMed published news for 2020 q4
SEC form 6
2020-11-20 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-11-05 16:08 ET
ResMed published news for 2020 q3
SEC form 10
2020-10-29 19:21 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-29 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-06 16:12 ET
ResMed published news for 2020 q3